-
How Africa vaccine production would boost global adjuvants market
SHEM OIRERE
September 15, 2021
The drive to expand vaccine manufacturing in Africa is gaining momentum with several new partnership agreements including technology transfer for the production of both malaria and COVID-19 vaccine...
-
Model ADJG120 Ampoule Automatic Inspection Machine
PharmaSources.com
December 27, 2017
ADJG120 ampoule automatic detection machine introduced
-
China's First Domestic CTLA-4 Inhibitor, in Combination With Sintilimab as Neoadjuvant Treatment for Colon Cancer
PR Newswire
February 24, 2025
NMPA Accepts NDA and Grants Priority Review Designation to combine with Sintilimab as Treatment for Colon Cancer.
-
NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon C
PR Newswire
February 24, 2025
Innovent's NDA for ipilimumab with sintilimab as neoadjuvant for MSI-H/dMMR colon cancer is accepted and gets Priority Review, based on trial results.
-
Merck’s Keytruda obtains EC approval as adjuvant therapy for kidney cancer
Pharmaceutical-Technology
January 28, 2022
In a Phase III trial, Keytruda lowered the disease recurrence or mortality risk by 32% versus placebo.
-
Avanti & Croda-Denmark: Advancing Vaccine Adjuvant Research
CPhIonline
January 24, 2022
In 2020, researchers at Verndari, Inc. investigated a novel microarray skin patch vaccine incorporating subunit glycoprotein antigens and liposomal adjuvants into a trehalose co-formulation.
-
Asieris Announces the World's First Patient Dose Administered in Combination of Asieris'APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients
prnasia
January 04, 2022
Asieris Pharmaceuticals (Asieris), a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors, today announced that the world's first patient dose...
-
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® as Adjuvant Therapy for Renal Cell Carcinoma
AmericanPharmaceuticalReview
December 20, 2021
Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA...
-
NICE recommends monotherapy for adjuvant treatment of stage 3 melanoma
pharmatimes
December 17, 2021
The approval follows a successful period of monitoring and patient access through the Cancer Drugs Fund.
-
Medicago and GSK Announce Positive Phase 3 Efficacy and Safety Results for Adjuvanted Plant-Based COVID-19 Vaccine Candidate
AmericanPharmaceuticalReview
December 09, 2021
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline announced positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago's plant-based COVID-19 vaccine candidate in...